The American College of Cardiology (ACC) released its lineup of late-breaking clinical trials to be presented at the scientific sessions March 29-31 in Washington, D.C.

Here they are by date:

Saturday, March 29

• Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed High-Risk for Surgery
• Main Results of SYMPLICITY HTN-3

Sunday, March 30

The first five presentations are part of a joint session of the ACC and JAMA.

• Effect of Inhibition of Lipoprotein-Associated Phospholipase A2 with Darapladib on Ischemic Events in Patients with Chronic Coronary Heart Disease: The STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) Trial
• The Low-density Lipoprotein Cholesterol Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy - 2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
• Evaluation of the Dual PPAR-α/γ Agonist Aleglitazar to Reduce Cardiovascular Events in Patients with Acute Coronary Syndrome and Type 2 Diabetes Mellitus: the AleCardio Trial
• Two-year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer: the NOBORITM Biolimus-Eluting versus XIENCE^TM/PROMUS^TM Everolimus-eluting Stent Trial (NEXT)
• A Phase 3 Double-blind, Randomized Study to Assess the Safety and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of Statin
• Efficacy And Safety Of Colchicine In Patients With Multiple Recurrences Of Pericarditis: Results of A Multicenter, Double-blind, Placebo-controlled, Randomized Study (corp-2 Trial)
• The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation in Real World Patients with Uncontrolled Hypertension
• One Year Follow-up of the Melody Transcatheter Pulmonary Valve Multicenter Post Approval Study
• Long-term Survival with Cardiac Resynchronization Therapy in Patients with Mild Heart Failure
• Negative High-Sensitive Troponins in the Emergency Department and Risk of Myocardial Infarction

Monday, March 31

The first five presentations are part of a joint session of the ACC and the New England Journal of Medicine.

• The Impact of Acetyl-Salicylic Acid on Major Arterial and Venous Complications in Patients Undergoing Noncardiac Surgery
• A Large International Trial Assessing the Effects of Clonidine on Major Arterial Events in Patients Having Noncardiac Surgery (POISE 2)
• Steroids in Cardiac Surgery Trial (SIRS)
• Metformin in Acute Myocardial Infarction
• Effect of Bariatric Surgery vs. Intensive Medical Therapy on Long-term Glycemic Control and Complications of Diabetes: 3-Year STAMPEDE Trial Results
• One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry
• A Randomized Comparison of Self-Expandable and Balloon-Expandable Prostheses in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement - The CHOICE Trial
• Unfractionated Heparin versus Bivalirudin in Primary Percutaneous Coronary Intervention: A Unique Randomized Controlled Trial with Consecutive, Unselected Patient Enrollment (using Delayed Consent), Designed to Reflect Real-World, Contemporary Practice
• Bare Metal vs. Zotarolimus-eluting stent in Uncertain Drug-eluting Stent Candidates: A Randomized Controlled Trial
• Autotransplantation of Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Severe Ischemic Heart Failure: The MSC-HF Trial